Scientific Program

Conference Series Ltd invites all the participants across the globe to attend World Eye and Vision Congress Dubai, UAE.

Day 1 :

Keynote Forum

Dr Ajay Tripathi

Russells Hall Hospital, United Kingdom

Keynote: Orbital Inflammation- The myths and the facts

Time : 09:45-10:20

OMICS International Eye 2018 International Conference Keynote Speaker Dr Ajay Tripathi photo
Biography:

Mr A. Tripathi did his masters in Ophthalmology in India and then completed fellowships in Ophthalmology from The Royal College of Physicians and Surgeons of Glasgow, The Royal College of Surgeons Edinburgh and The Royal College of Ophthalmologists, London. He completed his super speciality fellowships in lid, lacrimal and orbital surgery from University of Leicester and Cambridge University UK. He is working as a consultant in UK since 2007 and is also an Honorary Senior Lecturer in University of Birmingham. He is actively involved in teaching and training programmes within UK, Europe and India. He has a number of research publications in international peer reviewed journals. In addition to his professional committments, Mr Tripathi is an accomplished singer, actor and writer and he has written many plays, poetries and has directed many plays. He regularly does musical concerts throughout the world to support various charitable organisations.

Abstract:

Orbital inflammation is an important, yet often misdiagnosed and mismanaged clinical condition. A delayed diagnosis or inappropriate treatment could have a long lasting impact on an individual’s vision. In this keynote address the author dispells various common myths about orbital inflammation and explains simple facts about the condition with the help of a number of clinical case presentations. The role of imaging and some other special onvestigations is also discussed.

 

OMICS International Eye 2018 International Conference Keynote Speaker John S Jarstad photo
Biography:

Dr. Jarstad is an Associate Professor and Director of Cataract & Refractive Surgery at University of Missouri.  He is a graduate of Brigham Young University (B.S.), University of Washington Medical School (Seattle WA) and completed an Internship and Residency at the Mayo Clinic in Rochester MN in ophthalmology.  He was a medical student research fellow at the N.I.H. Bethesda MD.   Dr. Jarstad is past president of the Washington State Academy of Eye Physicians and Surgeons, a member of the American Society of Cataract and Lasik surgeons, and was elected to the Royal Society of Medicine - United Kingdom in 2006.  Dr. Jarstad is the author of one book and more than 90 publications and presentations in the eye surgery literature. He is the inventor of the Jarstad Refractive Cataract Surgery Marker, the first injectable foldable lens inserter (Chiron Passport) and an FDA phase I, II and III clinical investigator for medications and phaco machines used in eye surgery.  Along with family members, he has participated in 41 short term medical missions to Egypt, Zimbabwe, Angola, Madagascar and Nigeria Africa, the Philippines, Vietnam, Cambodia, Indonesia and North Korea.

 

Abstract:

Cornea collagen crosslinking has emerged as a highly successful treatment for keratoconus and post-LASIK ectasia. The use of topical concentrated riboflavin solution, along with a calibrated ultraviolet light source has been shown to successfully cross-link and stiffen the cornea align storm and arrest and in most cases, reduce the effect of corn steepening in  several degenerative cornea conditions including keratoconus and post-refractive surgery ectasia.

  

Cornea cross-linking with the Avedro commercial UV light source and concentrated topical riboflavin solution produced in a standard dose is widely accepted and was FDA approved in the USA in 2016 as a treatment for Keratoconus and post refractive surgery ectasia.  The high financial treatment cost, along with the high cost of the Avedro machine, has limited ophthalmologist’s and patient’s access to this new effective treatment.

 

We report cases at three separate institutions where patients, either on the own or under the suggestion of their ophthalmologist ingested high doses of dietary riboflavin (Vitamin B2)  and were exposed to 15 minutes per day of direct sunlight and noted within 6 months to experience a significant amount of cornea flattening by both topographic and keratometric measurements.  No adverse effects were observed or reported in patients taking up to 1500 mg of dietary riboflavin per day and spending 15 minutes daily outdoors walking briskly facing the sun without sunglasses.    

 

We conclude that high-dose dietary riboflavin may have a place in the treatment of keratoconus and post-refractive surgery kerectasia as an economical alternative or adjunctive form of treatment.  It may be especially useful in paediatric and pregnant patients who are more likely to regress after commercial cross-linking therapy.